Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL GRH PHARMA : revenue, balance sheet and financial ratios

SPFPL GRH PHARMA is a French company founded 6 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in CHATEAU-RENAULT (37110), this company of category PME shows in 2022 a net income negative of -770€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL GRH PHARMA (SIREN 880374178)
Indicator 2022 2021
Revenue N/C N/C
Net income -770 € -1 936 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2022, SPFPL GRH PHARMA records a net loss of 770 €. This deficit will reduce equity on the balance sheet.

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-770 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at -1704%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -6%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

-1703.634%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

-6.204%

Solvency indicators evolution
SPFPL GRH PHARMA

Sector positioning

Debt ratio
-1703.63 2022
2021
2022
Q1: 0.04
Med: 14.14
Q3: 118.39
Excellent

In 2022, the debt ratio of SPFPL GRH PHARMA (-1703.63) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
-6.2% 2022
2021
2022
Q1: 18.05%
Med: 62.02%
Q3: 91.75%
Average

In 2022, the financial autonomy of SPFPL GRH PHARMA (-6.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Positioning of SPFPL GRH PHARMA in its sector

Comparison with sector Fonds de placement et entités financières similaires

Similar companies (Fonds de placement et entités financières similaires)

Compare SPFPL GRH PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about SPFPL GRH PHARMA

What is the revenue of SPFPL GRH PHARMA ?

The revenue of SPFPL GRH PHARMA is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL GRH PHARMA profitable?

SPFPL GRH PHARMA recorded a net loss in 2022.

Where is the headquarters of SPFPL GRH PHARMA ?

The headquarters of SPFPL GRH PHARMA is located in CHATEAU-RENAULT (37110), in the department Indre-et-Loire.

Where to find the tax return of SPFPL GRH PHARMA ?

The tax return of SPFPL GRH PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL GRH PHARMA operate?

SPFPL GRH PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.